Marian Chu

South Korea

Staff Writer at BioWorld

Featured in: Favicon

bioworld.com Favicon

koreabiomed.com Favicon

corporatecompliance.org Favicon

biospace.com

Articles

Nibec stock soars 30% on $435M peptide deal with US biotech

1 week ago | bioworld.com | Marian Chu

Pfizer Inc. is paying $1.25 billion up front and up to $4.8 billion in milestone payments to gain global, ex-China rights to SSGJ-707, a PD-1/VEGF bispecific...
Epimab sells bispecific T-cell engager to Juri in $210M deal

1 week ago | bioworld.com | Marian Chu

Home » Epimab sells bispecific T-cell engager to Juri in $210M deal BioWorld briefs for May 28, 2025. BioWorld MedTech briefs for May 27, 2025. A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments. Itâ€™s a step in the direction the company... Salvia Bioelectronics BV raised $60 million in a series B financing round for its minimally invasive implantable neuromodulation device, Mysalvia therapy, which...
GC Genome plans $30M IPO to diversify genomic products, suppliers

1 week ago | bioworld.com | Marian Chu

Pfizer Inc. is paying $1.25 billion up front and up to $4.8 billion in milestone payments to gain global, ex-China rights to SSGJ-707, a PD-1/VEGF bispecific...
Cancer drug specialist Immuneoncia raises $24M in Kosdaq listing

1 week ago | bioworld.com | Marian Chu

Cancer drug specialist Immuneoncia raises $24M in Kosdaq listingImmuneoncia Therapeutics Inc. raised ₩33.9 billion (US$24 million) from its Kosdaq listing May 19. Shares closed at ₩7,500 – 108% higher than its offering price of ₩3,600 per share. Immuneoncia, a joint venture founded in 2016 between Seoul, South Korea-based Yuhan Corp. and San Diego-based Sorrento Therapeutics Inc., noted that the funds will support R&D operations until 2026.
Alteogen merges two subsidiaries, forming Alteogen Biologics

1 week ago | bioworld.com | Marian Chu

Home » Alteogen merges two subsidiaries, forming Alteogen Biologics BioWorld briefs for May 23, 2025. BioWorld MedTech briefs for May 23, 2025. BioWorld Asia briefs for May 20, 2025 Vertex Pharmaceuticals Inc. has synthesized sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain. Pfizer Inc.
Alteogen merges two subsidiaries, forming Alteogen Biologics

2 weeks ago | bioworld.com | Marian Chu

Sanofi SA made good on its plan to bear down on M&A by agreeing to buy Vigil Neuroscience Inc. for $8 per share (NASDAQ:VIGL). Included in the transaction is a...
Samsung Biologics to spin off biosimilar subsidiary Samsung Bioepis

2 weeks ago | bioworld.com | Marian Chu

Samsung Biologics to spin off biosimilar subsidiary Samsung BioepisSamsung Biologics Co. Ltd. plans to establish a new holding company and to spin off its biosimilar division, Samsung Bioepis Co. Ltd., by October. The corporate restructuring will draw clear lines between Samsung Biologics’ contract development and manufacturing organization operations and Samsung Bioepis’ biosimilar business. BioWorld Analysis and data insight Newco news Regulatory Cancer Immune Biosimilar Asia-Pacific
Cancer drug specialist Immuneoncia raises $24M in Kosdaq listing

2 weeks ago | bioworld.com | Marian Chu

Home » Cancer drug specialist Immuneoncia raises $24M in Kosdaq listingCancer drug specialist Immuneoncia raises $24M in Kosdaq listingImmuneoncia Therapeutics Inc. raised ₩33.9 billion (US$24 million) from its Kosdaq listing May 19. Shares closed at ₩7,500 – 108% higher than its offering price of ₩3,600 per share. BioWorld Financings Cancer Immuno-oncology Monoclonal antibody IPO Asia-Pacific
Pfizer bets $6B+ on 3Sbio’s bispecific PD-1/VEGF antibody

2 weeks ago | bioworld.com | Marian Chu

With FDA vaccine nod, Novavax takes ACIP of new COVID-19 rulesFrets about how the new federal administration might affect prospects for vaccines were quelled at least somewhat by the U.S. FDA green light for Novavax Inc.’s...
Rznomics in $1.3B Lilly pact to make hearing loss RNA editor drug

2 weeks ago | bioworld.com | Marian Chu

Home » Rznomics in $1.3B Lilly pact to make hearing loss RNA editor drugRznomics in $1.3B Lilly pact to make hearing loss RNA editor drugRznomics Inc. scored a potential ₩1.9 trillion (US$1.35 billion) global license option agreement with Eli Lilly and Co. to codevelop a novel RNA editing gene therapy to treat hereditary hearing loss. BioWorld Asia Deals and M&A License Gene therapy Asia-Pacific U.S. FDA